@article {Hartley2020.08.21.20178863, author = {Paul D. Hartley and Richard L. Tillett and David P. AuCoin and Joel R. Sevinsky and Yanji Xu and Andrew Gorzalski and Mark Pandori and Erin Buttery and Holly Hansen and Michael A. Picker and Cyprian C. Rossetto and Subhash C. Verma}, title = {Genomic surveillance revealed prevalence of unique SARS-CoV-2 variants bearing mutation in the RdRp gene among Nevada patients}, elocation-id = {2020.08.21.20178863}, year = {2020}, doi = {10.1101/2020.08.21.20178863}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Patients with signs of COVID-19 were tested with CDC approved diagnostic RT-PCR for SARS-CoV-2 using RNA extracted from nasopharyngeal/nasal swabs. In order to determine the variants of SARS-CoV-2 circulating in the state of Nevada, 200 patient specimens from positively identified cases were sequenced through our robust protocol for sequencing SARS-CoV-2 genomes from the nasopharyngeal or nasal swabs. This protocol enabled the identification of specific nucleotide variants including those coding for D614G and clades defining mutations. Additionally, these sequences were used for determining the phylogenetic relationships of SARS-CoV-2 genomes of public health importance occurring in the state of Nevada. Our study reports the occurrence of a novel variant in the nsp12 (RdRp-RNA dependent RNA Polymerase) protein at residue 323 (314aa of orf1b) to Phenylalanine (F) from Proline (P), present in the original isolate of SARS-CoV-2 (Wuhan-Hu-1). This 323F variant is found at a very high frequency (46\% of the tested specimen) in Northern Nevada, possibly because the virus accumulated this mutation while circulating in the community and the shelter in place orders restricted the introduction and spread of other variants into this region. Structural modeling of the RdRp with P323F variant did not show any significant difference in protein conformation, but the phenotypic effect is unknown and an area of active investigation. In conclusion, our results highlight the introduction and spread of specific SARS-CoV-2 variants at very high frequency within a distinct geographic location that is important for clinical and public health perspectives in understanding the evolution and transmission of SARS-CoV-2.IMPORTANCE SARS-COV-2 genomes accumulate nucleotide mutations while passing in the human population and these mutations may confer phenotypic differences including altered immune response and anti-viral drug resistance. We developed a robust workflow to sequence SARS-CoV-2 directly from the nasal/nasopharyngeal swabs containing even a very low viral loads (\>35 Ct value samples). Our protocol does not rely on amplicon based sequencing strategies nor the need of passing the virus into tissue culture thus reduces the possibility of an introduction of laboratory-adapted mutations. Sequences of SARS-CoV-2 from the patients of the state of Nevada during early months of the pandemic identified a rare mutation in the RdRp protein (P323F). This mutation occurred at a very high frequency in the variants of SARS-CoV-2 circulating Northern Nevada. Identification of such variants is important for clinical and public health perspectives in understanding transmission mediated evolution of SARS-CoV-2 variants and their implications on therapeutics and diagnostics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNevada IDeA Network of Biomedical Research Excellence (INBRE) from the National Institute of General Medical Sciences (GM 103440 and GM 104944) from the National Institutes of Health (NIH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Deidentified human specimens (nasal and nasopharyngeal swabs) were used for the extraction of viral RNA all the experiments were done in accordance with guidelines of the University of Nevada, Reno. The University of Nevada, Reno Institutional Review Board (IRB) reviewed this project and determined this study to be EXEMPT FROM IRB REVIEW according to federal regulations and University policy. The Environmental and Biological Safety committee of the University of Nevada, Reno, approved methods and techniques used in this study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://www.ncbi.nlm.nih.gov/bioproject/657893 https://www.ncbi.nlm.nih.gov/bioproject/657893}, URL = {https://www.medrxiv.org/content/early/2020/09/11/2020.08.21.20178863}, eprint = {https://www.medrxiv.org/content/early/2020/09/11/2020.08.21.20178863.full.pdf}, journal = {medRxiv} }